Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer
批准号:
8433545
负责人:
M. Rita Young
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-01 至 2016-12-31
关键词:
4-Nitroquinoline-1-oxideAfghanistanAgingAlcoholsAntigensAttentionAutologousBurn injuryCarcinogensCellsConditioned Culture MediaDendritic CellsDevelopmentExhibitsExposure toGoalsGulf WarHead and Neck Squamous Cell CarcinomaHealthImmuneImmunityIncidenceInfiltrationInflammationInflammatoryInterferonsInterleukin-17Interleukin-2IraqLeadLesionLinkMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMediatingMilitary PersonnelMusPatientsPeptidesPhenotypePopulationPopulations at RiskPremalignantPrevalenceRecruitment ActivityRegulatory T-LymphocyteRisk FactorsRoleSmokingSpecificityT-LymphocyteTestingTissuesTobaccoTransforming Growth Factor betaTransforming Growth Factor beta ReceptorsTranslatingTumor AntigensVeteransbasecytokinehigh riskinhibitor/antagonistinterleukin-23malignant mouth neoplasmmouse modelnovel strategiesoral lesionpreventpublic health relevancereceptortumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Premalignant oral lesions have increased levels of Th17 cells, which are replaced with Treg as lesions become head and neck squamous cell carcinomas (HNSCC). This study aims to prevent progression of premalignant lesions to HNSCC by capitalizing on the anti-tumor effects of Th17 cells. The hypothesis of this study is that sustained stimulation of reactivity mediated b IFN-?-expressing Th17 cells in premalignant oral lesions can promote immunological defenses against premalignant lesions and, consequently, prevent HNSCC. The premise of this hypothesis is that Th17 cells can be potent producers of IFN-?, exhibit antigen-specific activity,
and recruit dendritic cells and Th1 T-cells. Also, our studies have shown (i) levels of IFN-?-expressing Th17 cells are increased in premalignant lesions, but are replaced with Treg during progression toward HNSCC, (ii) media conditioned by HNSCC skews the Th17 phenotype of cells from mice with premalignant lesions to a Treg phenotype, but IL-23 lessens the loss of Th17 cells, while neutralization of TGF? prevents development of Treg, (iii) inhibition of inflammation exacerbates lesion development. Our hypothesis will be tested in a carcinogen-induced mouse model in which premalignant oral lesions progress into HNSCC. In addition, studies will transition to assessing reactivity of Th17 cells from patients having premalignant oral lesions against autologous lesions. The following aims will test if sustaining the Th17 phenotype can result in protective immune activity against progression of premalignant lesions to HNSCC: 1. To sustain the Th17- IFN-? + cell phenotype as premalignant oral lesions progress toward HNSCC so as to stimulate lesion-specific immune reactivity and reduce progression to malignancy. a. Determine if sustaining the Th17 phenotype by stabilizing Th17 cells with IL-23 and/or preventing skewing toward Treg cells with a TGF-? receptor inhibitor sustains levels of IFN-? -producing Th17 cells with specificity toward premalignant lesions and HNSCC. b. Determine if stabilizing the Th17- IFN-? + phenotype stimulates immune infiltration that is reactive toward premalignant lesions and against the development of HNSCC. 2. To determine the extent to which Th17 cells from patients bearing premalignant oral lesions exhibit specificity toward autologous lesions and whether this activity can be further stimulated with peptides derived from tumor antigens that are prominently expressed on premalignant lesions and HNSCC. The proposed studies are expected to show that the Th17+ IFN-? + phenotype can promote protective immunity against premalignant oral lesions. Since a high proportion of premalignant oral lesions progress to HNSCC, protective immunity against lesions is expected to translate into reduced development of HNSCC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer
-
批准号:8774217
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:M. Rita Young
-
依托单位:
Sustaining a Th17 Phenotype to Prevent Premalignant Lesion Progression to Cancer
-
批准号:8624540
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:M. Rita Young
-
依托单位:
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
-
批准号:8586842
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
-
批准号:7754439
-
项目类别:
-
资助金额:$36.14万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
-
批准号:7910667
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
-
批准号:8195963
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
-
批准号:7574715
-
项目类别:
-
资助金额:$26.15万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
-
批准号:7928678
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
-
批准号:8010932
-
项目类别:
-
资助金额:$25.36万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
-
批准号:8390418
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
-
批准号:8197942
-
项目类别:
-
资助金额:$25.36万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
-
批准号:8403804
-
项目类别:
-
资助金额:$23.84万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
-
批准号:7785523
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:M. Rita Young
-
依托单位:
Macrophage-driven progression of premalignant oral lesions toward invasiveness
-
批准号:7667479
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2008
-
负责人:M. Rita Young
-
依托单位:
Macrophage-driven progression of premalignant oral lesions toward invasiveness
-
批准号:7516333
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2008
-
负责人:M. Rita Young
-
依托单位:
Macrophage-driven progression of premalignant oral lesions toward invasiveness
-
批准号:8075563
-
项目类别:
-
资助金额:$30.25万
-
财政年份:2008
-
负责人:M. Rita Young
-
依托单位:
Macrophage-driven progression of premalignant oral lesions toward invasiveness
-
批准号:7872962
-
项目类别:
-
资助金额:$31.19万
-
财政年份:2008
-
负责人:M. Rita Young
-
依托单位:
Blocking angiogenesis by targeting PP-2A pathways
-
批准号:7228890
-
项目类别:
-
资助金额:$23.92万
-
财政年份:2003
-
负责人:M. Rita Young
-
依托单位:
Blocking angiogenesis by targeting PP-2A pathways
-
批准号:6899902
-
项目类别:
-
资助金额:$25.23万
-
财政年份:2003
-
负责人:M. Rita Young
-
依托单位:
Blocking angiogenesis by targeting PP-2A pathways
-
批准号:7079434
-
项目类别:
-
资助金额:$24.64万
-
财政年份:2003
-
负责人:M. Rita Young
-
依托单位:
海外基金